X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to focus on the development of ABBV-303 in combination with ABBV-181, which is being evaluated in the Phase I clinical trial studies for the treatment of neoplasms.
Lead Product(s): ABBV-303,Budigalimab
Therapeutic Area: Oncology Product Name: ABBV-303
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 05, 2024
Details:
The collaboration is designed to evaluate and combine DF1001, which is a new molecule that targets natural killer cells and T-cell activation signals, with Gilead's Trop-2-directed antibody-drug conjugate in the treatment of metastatic breast and non-small cell lung cancer.
Lead Product(s): Df1001,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: DF1001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2024
Details:
Dragonfly lead product candidate DF6215, which is IL-2 Immunotherapy. Currently, it is being evaluated in the clinical development with patients for the treatment of advanced solid tumors.
Lead Product(s): DF6215
Therapeutic Area: Oncology Product Name: DF6215
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
DF6002 is a monovalent IL12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses.
Lead Product(s): DF6002,Nivolumab
Therapeutic Area: Oncology Product Name: DF6002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
The Company’s first TriNKET, DF1001, entered Phase 2 trials this month after being well-tolerated in Phase 1 with encouraging clinical responses, including showing tumor burden reductions across several tumor types, including in HER2-low and heavily pre-treated patients.
Lead Product(s): Df1001,Nivolumab
Therapeutic Area: Oncology Product Name: DF1001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
DF1001 was well-tolerated with no dose limiting toxicities during dose escalation in the Phase 1 study. The study showed encouraging pharmacodynamic effects including infiltration of NK cells and T cells into tumors.
Lead Product(s): Df1001,Nivolumab
Therapeutic Area: Oncology Product Name: DF1001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
Through the collaboration, Nona Biosciences will provide Dragonfly Therapeutics with access to the HCAb technologies as well as antibody generation services for the targets designated by Dragonfly Therapeutics.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Nona Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 21, 2022
Details:
Under the agreement Merck has exercised its option to license exclusive worldwide intellectual property rights on its second immunotherapy candidate DF8001 (MK-4464), developed using the TriNKET™ technology platform.
Lead Product(s): MK-4464,Pembrolizumab
Therapeutic Area: Oncology Product Name: DF8001
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration November 01, 2022
Details:
Under the agreement, Gilead will receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy, DF7001. Gilead also gains worldwide rights to develop and commercialize NK cell engager programs using the Dragonfly TriNKET™ platform.
Lead Product(s): DF7001
Therapeutic Area: Oncology Product Name: DF7001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: $300.0 million
Deal Type: Collaboration May 02, 2022
Details:
DF6002/BMS-9896415, a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses.
Lead Product(s): BMS-9896415,Nivolumab
Therapeutic Area: Oncology Product Name: DF6002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
